The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

Flare and persistently active disease are prevalent in a multinational cohort study of patients with systemic lupus erythematosus, with some having persistently active disease without flare.

Inflammatory-type lesions and myelopathies found on MRI were significantly associated with attribution of neuropsychiatric events to systemic lupus erythematosus. Magnetic resonance imaging (MRI) ...

New research by Swansea University and Cambridge University has revealed the causes and devastating impacts of delays—that ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in ...

GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support ...

One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

Called enpatoran, the agent targets the Toll-like receptor (TLR) species 7 and 8. Some 50%-60% of patients with systemic ...

A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease.

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...

SLE Disease Activity Index. Lupus 8(6), 462-465 (1999). Maddison PJ: Systemic lupus erythematosus in the ... Is chloroquine obsolete in treatment of rheumatic disease? Lancet 1(8112), 371-373 ...